NPPB and hydrops fetalis: Post-hoc analysis of the PROTECT study focusing on NT-proBNP “nonresponse” during HF management (NT-proBNP > 1000 pg/mL) found that a decreasing NT-proBNP was associated with better clinical outcomes, while a rising NT-proBNP correlated with increased cardiovascular event rates [76].